Working… Menu

Special Drug Use Investigation of EYLEA for Myopic Choroidal Neovascularization

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02260687
Recruitment Status : Completed
First Posted : October 9, 2014
Last Update Posted : September 19, 2019
Regeneron Pharmaceuticals
Information provided by (Responsible Party):

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : April 2, 2018
Actual Study Completion Date : August 22, 2018